NCT01274637View on ClinicalTrials.gov

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Venous ThromboembolismPostpartum
Interventions
DRUG

Dalteparin Sodium

5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.

Trial Locations (7)

22908

University of Virginia Medical Center, Charlottesville

98104

Puget Sound Blood Center, Seattle

Unknown

Royal Alexandra Hospital, Edmonton

Sunnybrook Health Sciences Centre, Toronto

SMBD Jewish General Hospital, Montreal

L8N 3Z5

McMaster University Medical Centre, Hamilton

K1H 8L6

Ottawa Hospital General Campus & Civic Campus, Ottawa

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Hospital Research Institute

OTHER